|
1.
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Socialstyrelsen Ec: Cancer incidence in
Sweden 2008. 2008
|
|
3.
|
Vizcaino AP, Moreno V, Bosch FX, Munoz N,
Barros-Dios XM and Parkin DM: International trends in the incidence
of cervical cancer: I. Adenocarcinoma and adenosquamous cell
carcinomas. Int J Cancer. 75:536–545. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Smith HO, Tiffany MF, Qualls CR and Key
CR: The rising incidence of adenocarcinoma relative to squamous
cell carcinoma of the uterine cervix in the United States - a
24-year population-based study. Gynecol Oncol. 78:97–105. 2000.
|
|
5.
|
Bray F, Carstensen B, Moller H, et al:
Incidence trends of adenocarcinoma of the cervix in 13 European
countries. Cancer Epidemiol Biomarkers Prev. 14:2191–2199. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Pettersson BF, Andersson S, Hellman K and
Hellstrom AC: Invasive carcinoma of the uterine cervix associated
with pregnancy: 90 years of experience. Cancer. 116:2343–2349.
2010.PubMed/NCBI
|
|
7.
|
Etherington IJ and Luesley DM:
Adenocarcinoma in situ of the cervix-controversies in diagnosis and
treatment. J Low Genit Tract Dis. 5:94–98. 2001.PubMed/NCBI
|
|
8.
|
Gien LT, Beauchemin MC and Thomas G:
Adenocarcinoma: a unique cervical cancer. Gynecol Oncol.
116:140–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Bosch FX and Munoz N: The viral etiology
of cervical cancer. Virus Res. 89:183–190. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Andersson S, Larson B, Hjerpe A, et al:
Adenocarcinoma of the uterine cervix: the presence of human
papillomavirus and the method of detection. Acta Obstet Gynecol
Scand. 82:960–965. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Castellsague X, Diaz M, de Sanjose S, et
al: Worldwide human papillomavirus etiology of cervical
adenocarcinoma and its cofactors: implications for screening and
prevention. J Natl Cancer Inst. 98:303–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Andersson S, Wallin KL, Hellstrom AC, et
al: Frequent gain of the human telomerase gene TERC at 3q26 in
cervical adenocarcinomas. Br J Cancer. 95:331–338. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Gur G, Rubin C, Katz M, et al: LRIG1
restricts growth factor signaling by enhancing receptor
ubiquitylation and degradation. EMBO J. 23:3270–3281. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Laederich MB, Funes-Duran M, Yen L, et al:
The leucine-rich repeat protein LRIG1 is a negative regulator of
ErbB family receptor tyrosine kinases. J Biol Chem.
279:47050–47056. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Miller JK, Shattuck DL, Ingalla EQ, et al:
Suppression of the negative regulator LRIG1 contributes to ErbB2
overexpression in breast cancer. Cancer Res. 68:8286–8294. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Shattuck DL, Miller JK, Laederich M, et
al: LRIG1 is a novel negative regulator of the Met receptor and
opposes Met and Her2 synergy. Mol Cell Biol. 27:1934–1946. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ledda F, Bieraugel O, Fard SS, Vilar M and
Paratcha G: Lrig1 is an endogenous inhibitor of Ret receptor
tyrosine kinase activation, downstream signaling, and biological
responses to GDNF. J Neurosci. 28:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hedman H and Henriksson R: LRIG inhibitors
of growth factor signalling - double-edged swords in human cancer?
Eur J Cancer. 43:676–682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Powell AE, Wang Y, Li Y, et al: The
pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker
that functions as a tumor suppressor. Cell. 149:146–158. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Krig SR, Frietze S, Simion C, et al: Lrig1
is an estrogen-regulated growth suppressor and correlates with
longer relapse-free survival in ERalpha-positive breast cancer. Mol
Cancer Res. 9:1406–1417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Lindstrom AK, Ekman K, Stendahl U, et al:
LRIG1 and squamous epithelial uterine cervical cancer: correlation
to prognosis, other tumor markers, sex steroid hormones, and
smoking. Int J Gynecol Cancer. 18:312–317. 2008. View Article : Google Scholar
|
|
22.
|
Tanemura A, Nagasawa T, Inui S and Itami
S: LRIG-1 provides a novel prognostic predictor in squamous cell
carcinoma of the skin: immunohistochemical analysis for 38 cases.
Dermatol Surg. 31:423–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Holmlund C, Haapasalo H, Yi W, et al:
Cytoplasmic LRIG2 expression is associated with poor
oligodendroglioma patient survival. Neuropathology. 29:242–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Hedman H, Lindstrom AK, Tot T, Stendahl U,
Henriksson R and Hellberg D: LRIG2 in contrast to LRIG1 predicts
poor survival in early-stage squamous cell carcinoma of the uterine
cervix. Acta Oncol. 49:812–815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Lindstrom AK, Asplund A and Hellberg D:
Correlation between LRIG1 and LRIG2 expressions and expression of
11 tumor markers, with special reference to tumor suppressors, in
CIN and normal cervical epithelium. Gynecol Oncol. 122:372–376.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Andersson S, Rylander E, Larson B, et al:
Types of human papillomavirus revealed in cervical adenocarcinomas
after DNA sequencing. Oncol Rep. 10:175–179. 2003.PubMed/NCBI
|
|
27.
|
Guo D, Nilsson J, Haapasalo H, et al:
Perinuclear leucine-rich repeats and immunoglobulin-like domain
proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
Acta Neuropathol. 111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Klussmann JP, Gultekin E, Weissenborn SJ,
et al: Expression of p16 protein identifies a distinct entity of
tonsillar carcinomas associated with human papillomavirus. Am J
Pathol. 162:747–753. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Sano T, Oyama T, Kashiwabara K, Fukuda T
and Nakajima T: Expression status of p16 protein is associated with
human papillomavirus oncogenic potential in cervical and genital
lesions. Am J Pathol. 153:1741–1748. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Muller S, Flores-Staino C, Skyldberg B, et
al: Expression of p16INK4a and MIB-1 in relation to histopathology
and HPV types in cervical adenocarcinoma. Int J Oncol. 32:333–340.
2008.PubMed/NCBI
|
|
31.
|
Seoud M, Tjalma WA and Ronsse V: Cervical
adenocarcinoma: moving towards better prevention. Vaccine.
29:9148–9158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Tenti P, Romagnoli S, Silini E, et al:
Human papillomavirus types 16 and 18 infection in infiltrating
adenocarcinoma of the cervix: PCR analysis of 138 cases and
correlation with histologic type and grade. Am J Clin Pathol.
106:52–56. 1996.
|
|
33.
|
Andersson S, Rylander E, Larsson B, Strand
A, Silfversvard C and Wilander E: The role of human papillomavirus
in cervical adenocarcinoma carcinogenesis. Eur J Cancer.
37:246–250. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Attner P, Du J, Nasman A, et al: Human
papillomavirus and survival in patients with base of tongue cancer.
Int J Cancer. 128:2892–2897. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Hammarstedt L, Lindquist D, Dahlstrand H,
et al: Human papillomavirus as a risk factor for the increase in
incidence of tonsillar cancer. Int J Cancer. 119:2620–2623. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Krane JF, Granter SR, Trask CE, Hogan CL
and Lee KR: Papanicolaou smear sensitivity for the detection of
adenocarcinoma of the cervix: a study of 49 cases. Cancer. 93:8–15.
2001. View Article : Google Scholar : PubMed/NCBI
|
